Project Summary Cardiomyopathy is a disorder with high heterogeneity: >100 genes have been linked to different types of cardiomyopathy, such as hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM); patients with the same mutation can manifest highly variable disease onset and severity, presumably because of different genetic and environmental factors. However, the identity of genetic modifiers remains largely unknown. To address the need, our team has been leading the development of adult zebrafish as a vertebrate model for cardiomyopathy. During the previous 2 funding cycles, we developed a novel forward genetic screening strategy for discovering modifier genes for doxorubicin (DOX)–induced cardiomyopathy (DIC). Here, we plan to extend this approach to inherited cardiomyopathies. We have generated substantial preliminary data to prove the feasibility of the proposal, including the identification of 5 original DIC modifier genes and 4 additional candidate DIC modifier genes, the generation of a zebrafish model of BAG3 cardiomyopathy, the identification of mtor as a therapeutic modifier gene, and the establishment of an embryonic fish-adult fish- mouse drug assessment platform. Together, these data prompted us to test the central hypothesis of this proposal, which predicts that modifier genes for an inherited cardiomyopathy model can be identified via a forward genetic strategy in zebrafish, from which therapeutic target genes and related compounds can be rapidly discovered by efficient zebrafish genetics. The proposal is organized into 2 specific aims. In Specific Aim 1, we will test the hypothesis that a forward genetics-based approach is extendable to bag3 cardiomyopathy to identify therapeutic modifiers. We will determine phenotypic progression and variation in zebrafish bag3 KO, assess modifying effects of 9 DIC modifiers on bag3 cardiomyopathies, and then identify therapeutic modifiers for bag3 cardiomyopathy. We will elucidate underlying mechanism by transcriptome analysis. In Specific Aim 2, we will elucidate underlying mechanisms of the therapeutic effects of mTOR inhibition, prove autophagy-based therapy for bag3 cardiomyopathy, and repurpose FDA-approved autophagy- activating drugs to treat bag3 cardiomyopathy. It is anticipated that the novel strategy developed by this proposal will significantly advance prognostic test development, risk stratification, and personalized therapy for cardiomyopathies.
|Effective start/end date||4/1/11 → 4/30/23|
- National Heart, Lung, and Blood Institute: $401,656.00
- National Heart, Lung, and Blood Institute: $519,274.00
- National Heart, Lung, and Blood Institute: $522,502.00
- National Heart, Lung, and Blood Institute: $396,939.00
- National Heart, Lung, and Blood Institute: $455,958.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.